Evidence map›Paper›PMID 23816648›Full record

ArticleActa biomaterialia2013

Specific VEGF sequestering to biomaterials: influence of serum stability.

David G Belair, William L Murphy

Abstract read
In one paragraph

Article in Acta biomaterialia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Extracellular-Matrix-Mimetic Hydrogels by Using Nanomaterials.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Synthetic alternatives to Matrigel.Nature reviews. Materials · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Design of growth factor sequestering biomaterials.Chemical communications (Cambridge, England) · 2014
    Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David G BelairDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
William L Murphy
University of Wisconsin–Madison · US

Funding

Training Program in Translational Cardiovascular Science (TPTCS)T32HL007936 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Lee Lochbaum Eckhardt, Gail A Robertson · 2001 to 2026
$11.6M
Biomaterials for local regulation of growth factor signalingR01HL093282 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L. · 2009 to 2018
$3.3M
Modulation of the Immune System to Improve Ligament/Ligament Graft HealingR01AR059916 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L., VANDERBY, RAY · 2010 to 2014
$1.4M
Probing biochemical/biophysical influences on endothelial-mesenchymal transitionR21EB016381 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI MURPHY, WILLIAM L., SCHWARTZ, MICHAEL PAUL · 2013 to 2014
$399k
NHLBI NIH HHS R01 HL093282NHLBI NIH HHS R01HL093282NHLBI NIH HHS T32 HL007936-12NIAMS NIH HHS R01 AR059916NIBIB NIH HHS R21 EB016381
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) was originally discovered as a tumor-derived factor that is able to induce endothelial cell behavior associated with angiogenesis. It has been implicated during wound healing for the induction of endothelial cell proliferation, tube formation and blood vessel remodeling. However, previous investigations into the biological effect of VEGF concluded that a particular range of growth factor concentrations are required for healthy vasculature to form, motivating recent studies to regulate VEGF activity via molecular sequestering to biomaterials. Numerous VEGF sequestering strategies have been developed, and they have typically relied on extracellular matrix mimicking moieties that are not specific for VEGF and can affect many growth factors simultaneously. We describe here a strategy for efficient, specific VEGF sequestering with poly(ethylene glycol) (PEG) microspheres, using peptides designed to mimic VEGF receptor type 2 (VEGFR2). By immobilizing two distinct peptides with different serum stabilities, we examined the effect of serum on the specific interaction between peptide-containing PEG microspheres and VEGF. We addressed the hypothesis that VEGF sequestering in serum-containing solutions would be influenced by the serum stability of the VEGF-binding peptide. We further hypothesized that soluble VEGF could be sequestered in serum-containing cell culture media, resulting in decreased VEGF-dependent proliferation of human umbilical vein endothelial cells. We show that soluble VEGF concentration can be effectively regulated in serum-containing environments via specific molecular sequestering, which suggests potential clinical applications.

Indexed as

Biocompatible MaterialsCell ProliferationHumansHuman Umbilical Vein Endothelial CellsMicrospheresNorbornanesPeptide HydrolasesPeptidesPolyethylene GlycolsProtein BindingSerumVascular Endothelial Growth Factor ABiocompatible MaterialsNorbornanesPeptide HydrolasesPeptidesPolyethylene GlycolsVascular Endothelial Growth Factor AAngiogenesisExtracellular matrixPoly(ethylene glycol)SequestrationVEGF

Identifiers

PMID23816648
PMCPMC4149317
OpenAlexW2152932562

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.